The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
Investor's Business Daily on MSN
Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk
Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.
Vonoprazan treatment results in fewer episodes of nighttime heartburn and reduces symptom severity in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback